Canine Vaccines Market Size, Share, and Trends 2026 to 2035

Canine Vaccines Market (By Technology: Inactivated, Live Attenuated, Recombinant, Others; By Disease Type: Canine Influenza, Lyme Disease, Rabies, Leptospirosis, Others; By Route of Administration: Oral, Parenteral, Intranasal; By Distribution Channel: Veterinary Hospitals, Veterinary Clinics, Pharmacies & Drug Stores) - Global Industry Analysis, Size, Trends, Leading Companies, Regional Outlook, and Forecast 2026 to 2035

Last Updated : 02 Feb 2026  |  Report Code : 7514  |  Category : Healthcare   |  Format : PDF / PPT / Excel

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Canine Vaccines Market 

5.1. COVID-19 Landscape: Canine Vaccines Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Canine Vaccines Market, By Technology

8.1. Canine Vaccines Market, by Technology

8.1.1. Inactivated

8.1.1.1. Market Revenue and Forecast

8.1.2. Live Attenuated

8.1.2.1. Market Revenue and Forecast

8.1.3. Recombinant

8.1.3.1. Market Revenue and Forecast

8.1.4. Others

8.1.4.1. Market Revenue and Forecast

Chapter 9. Global Canine Vaccines Market, By Disease Type

9.1. Canine Vaccines Market, by Disease Type

9.1.1. Canine Influenza

9.1.1.1. Market Revenue and Forecast

9.1.2. Lyme Disease

9.1.2.1. Market Revenue and Forecast

9.1.3. Rabies

9.1.3.1. Market Revenue and Forecast

9.1.4. Leptospirosis

9.1.4.1. Market Revenue and Forecast

9.1.5. Others

9.1.5.1. Market Revenue and Forecast

Chapter 10. Global Canine Vaccines Market, By Route of Administration 

10.1. Canine Vaccines Market, by Route of Administration

10.1.1. Oral

10.1.1.1. Market Revenue and Forecast

10.1.2. Parenteral

10.1.2.1. Market Revenue and Forecast

10.1.3. Intranasal

10.1.3.1. Market Revenue and Forecast

Chapter 11. Global Canine Vaccines Market, By Distribution Channel 

11.1. Canine Vaccines Market, by Distribution Channel

11.1.1. Veterinary Hospitals

11.1.1.1. Market Revenue and Forecast

11.1.2. Veterinary Clinics

11.1.2.1. Market Revenue and Forecast

11.1.3. Pharmacies & Drug Stores

11.1.3.1. Market Revenue and Forecast

Chapter 12. Global Canine Vaccines Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Forecast, by Technology

12.1.2. Market Revenue and Forecast, by Disease Type

12.1.3. Market Revenue and Forecast, by Route of Administration

12.1.4. Market Revenue and Forecast, by Distribution Channel

12.1.5. U.S.

12.1.5.1. Market Revenue and Forecast, by Technology

12.1.5.2. Market Revenue and Forecast, by Disease Type

12.1.5.3. Market Revenue and Forecast, by Route of Administration

12.1.5.4. Market Revenue and Forecast, by Distribution Channel

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Forecast, by Technology

12.1.6.2. Market Revenue and Forecast, by Disease Type

12.1.6.3. Market Revenue and Forecast, by Route of Administration

12.1.6.4. Market Revenue and Forecast, by Distribution Channel

12.2. Europe

12.2.1. Market Revenue and Forecast, by Technology

12.2.2. Market Revenue and Forecast, by Disease Type

12.2.3. Market Revenue and Forecast, by Route of Administration

12.2.4. Market Revenue and Forecast, by Distribution Channel

12.2.5. UK

12.2.5.1. Market Revenue and Forecast, by Technology

12.2.5.2. Market Revenue and Forecast, by Disease Type

12.2.5.3. Market Revenue and Forecast, by Route of Administration

12.2.5.4. Market Revenue and Forecast, by Distribution Channel

12.2.6. Germany

12.2.6.1. Market Revenue and Forecast, by Technology

12.2.6.2. Market Revenue and Forecast, by Disease Type

12.2.6.3. Market Revenue and Forecast, by Route of Administration

12.2.6.4. Market Revenue and Forecast, by Distribution Channel

12.2.7. France

12.2.7.1. Market Revenue and Forecast, by Technology

12.2.7.2. Market Revenue and Forecast, by Disease Type

12.2.7.3. Market Revenue and Forecast, by Route of Administration

12.2.7.4. Market Revenue and Forecast, by Distribution Channel

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Forecast, by Technology

12.2.8.2. Market Revenue and Forecast, by Disease Type

12.2.8.3. Market Revenue and Forecast, by Route of Administration

12.2.8.4. Market Revenue and Forecast, by Distribution Channel

12.3. APAC

12.3.1. Market Revenue and Forecast, by Technology

12.3.2. Market Revenue and Forecast, by Disease Type

12.3.3. Market Revenue and Forecast, by Route of Administration

12.3.4. Market Revenue and Forecast, by Distribution Channel

12.3.5. India

12.3.5.1. Market Revenue and Forecast, by Technology

12.3.5.2. Market Revenue and Forecast, by Disease Type

12.3.5.3. Market Revenue and Forecast, by Route of Administration

12.3.5.4. Market Revenue and Forecast, by Distribution Channel

12.3.6. China

12.3.6.1. Market Revenue and Forecast, by Technology

12.3.6.2. Market Revenue and Forecast, by Disease Type

12.3.6.3. Market Revenue and Forecast, by Route of Administration

12.3.6.4. Market Revenue and Forecast, by Distribution Channel

12.3.7. Japan

12.3.7.1. Market Revenue and Forecast, by Technology

12.3.7.2. Market Revenue and Forecast, by Disease Type

12.3.7.3. Market Revenue and Forecast, by Route of Administration

12.3.7.4. Market Revenue and Forecast, by Distribution Channel

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Forecast, by Technology

12.3.8.2. Market Revenue and Forecast, by Disease Type

12.3.8.3. Market Revenue and Forecast, by Route of Administration

12.3.8.4. Market Revenue and Forecast, by Distribution Channel

12.4. MEA

12.4.1. Market Revenue and Forecast, by Technology

12.4.2. Market Revenue and Forecast, by Disease Type

12.4.3. Market Revenue and Forecast, by Route of Administration

12.4.4. Market Revenue and Forecast, by Distribution Channel

12.4.5. GCC

12.4.5.1. Market Revenue and Forecast, by Technology

12.4.5.2. Market Revenue and Forecast, by Disease Type

12.4.5.3. Market Revenue and Forecast, by Route of Administration

12.4.5.4. Market Revenue and Forecast, by Distribution Channel

12.4.6. North Africa

12.4.6.1. Market Revenue and Forecast, by Technology

12.4.6.2. Market Revenue and Forecast, by Disease Type

12.4.6.3. Market Revenue and Forecast, by Route of Administration

12.4.6.4. Market Revenue and Forecast, by Distribution Channel

12.4.7. South Africa

12.4.7.1. Market Revenue and Forecast, by Technology

12.4.7.2. Market Revenue and Forecast, by Disease Type

12.4.7.3. Market Revenue and Forecast, by Route of Administration

12.4.7.4. Market Revenue and Forecast, by Distribution Channel

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Forecast, by Technology

12.4.8.2. Market Revenue and Forecast, by Disease Type

12.4.8.3. Market Revenue and Forecast, by Route of Administration

12.4.8.4. Market Revenue and Forecast, by Distribution Channel

12.5. Latin America

12.5.1. Market Revenue and Forecast, by Technology

12.5.2. Market Revenue and Forecast, by Disease Type

12.5.3. Market Revenue and Forecast, by Route of Administration

12.5.4. Market Revenue and Forecast, by Distribution Channel

12.5.5. Brazil

12.5.5.1. Market Revenue and Forecast, by Technology

12.5.5.2. Market Revenue and Forecast, by Disease Type

12.5.5.3. Market Revenue and Forecast, by Route of Administration

12.5.5.4. Market Revenue and Forecast, by Distribution Channel

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Forecast, by Technology

12.5.6.2. Market Revenue and Forecast, by Disease Type

12.5.6.3. Market Revenue and Forecast, by Route of Administration

12.5.6.4. Market Revenue and Forecast, by Distribution Channel

Chapter 13. Company Profiles

13.1. Zoetis

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Virbac

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Elanco

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Merck & Co., Inc.

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. Ceva Santé Animale

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Boehringer Ingelheim International GmbH

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. Phibro Animal Health Corporation

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. IDEXX

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. HESTER BIOSCIENCES LIMITED

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. Indian Immunologicals Ltd.

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

Answer : The canine vaccines market size is expected to increase from USD 2.05 billion in 2025 to USD 4.23 billion by 2035.

Answer : The canine vaccines market is expected to grow at a compound annual growth rate (CAGR) of around 7.51% from 2026 to 2035.

Answer : The driving factors of the canine vaccines market are the increasing awareness among pet owners about the importance of vaccination and the rising prevalence of infectious diseases in dogs.

Answer : North America region will lead the global canine vaccines market during the forecast period 2026 to 2035.

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client